2/14/2013

A Colorado House committee passed a bill that would restrict pharmacists' ability to substitute less-expensive biologic drugs for those sold under brand names. Substitution would be allowed only if the FDA has deemed the biosimilar interchangeable with the brand-name drug for the specific indication and if the prescribing doctor allows the substitution.

Related Summaries